Granules India said its subsidiary Granules Pharmaceuticals received USFDA tentative approval for generic amphetamine extended-release tablets for ADHD, with FDA-determined eligibility for 180-day exclusivity.

Space station research informed a new FDA-approved cancer therapy.

The Health Ministry and WHO launched a December 2025 Delhi metro campaign delivering women's health and well-being messages to millions of commuters.

The FDA is investigating deaths potentially related to Covid-19 vaccines across all age groups amid controversy and claims from a leaked memo alleging infant deaths without evidence.

In Panama, twelve pairs of poison dart frogs have been translocated to combat a deadly fungal disease threatening amphibians, aiming to boost their population and ecological role.

A new study warns that wildfire smoke could lead to 71,000 excess deaths annually in the U.S. by 2050, with significant economic costs.

A new HIV prevention drug, Lenacapavir, will be available at a drastically reduced price in over 100 low-income countries, aiming to enhance access and combat the HIV epidemic.

A dengue fever outbreak in Sudan is overwhelming hospitals, with thousands of cases reported amid ongoing conflict and medical supply shortages.

The ACIP voted 8-3 to recommend against administering the MMRV vaccine to children under 4, citing risks of febrile seizures, amid concerns over declining vaccination rates.

Regeneron's garetosmab shows promise in treating fibrodysplasia ossificans progressiva, a rare condition causing abnormal bone growth, with regulatory submissions planned.

A recent study indicates that a higher weekly dose of Wegovy, a weight-loss drug, results in greater weight loss compared to the standard dose, albeit with increased side effects. Participants receiving the higher dose lost an average of 19% of their body weight, while those on the standard dose lost 16%. The study also noted significant reductions in prediabetes cases among participants. However, higher doses led to more gastrointestinal issues and skin sensations, suggesting that while benefits may outweigh risks for some, further trials are needed.

The World Health Organization reports a 5% increase in cholera cases and a 50% rise in deaths in 2024, with over 6,000 fatalities. The disease, preventable and treatable, is exacerbated by conflict, climate change, and inadequate sanitation. Africa, the Middle East, and Asia account for 98% of cases. Access to safe water, hygiene, and treatment is critical, as the global cholera crisis continues into 2025, with 31 countries reporting outbreaks.